About Site
Affordable Medicines Facility - malaria
Board
Business Opportunities
Country Coordinating Mechanisms
Civil Society and the Private Sector
Donate
Donors
Employment
Friends of the Fund
Global Fund Transformation
High Level Independent Review Panel
Innovative Financing
Local Fund Agents
Monitoring and Evaluation
National Strategy Applications
Office of Inspector General
Partnership Forum
Performance Based Funding
Private Sector
Pharmaceutical Procurement and Supply Management
Regional Meetings
Saving Lives: Stories from the Fight
Technical Evaluation and Reference Group
Technical Review Panel
Transitional Funding Mechanism
Ce contenu est seulement disponible en anglais
Overview of funding rounds: Rounds: 10 | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1
Overview of previous funding waves: Waves: Final | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1
Overview of previous funding phases:Phases: 1
Round 10 - December 2010
79 disease proposals (including HSS requests) approved in 64 different countries, totaling a maximum upper-ceiling of US$ 1.73 billion.
East Asia & the Pacific - US$ 211 million for 14 disease proposals (including HSS requests) in 11 countries Eastern Europe & Central Asia - US$ 208 million for 10 disease proposals in 8 countriesLatin America & the Caribbean - US$ 36 million for 8 disease proposals (including HSS requests) in 8 countriesNorth Africa & the Middle East - US$ 261 million for 14 disease proposals (including HSS requests) in 9 countriesSouth West Asia - US$ 82 million for 5 disease proposals (including HSS requests) in 5 countriesSub-Saharan Africa: East Africa - US$ 330 million for 9 disease proposals (including HSS requests) in 5 countriesSub-Saharan Africa: Southern Africa - US$ 336 million for 7 disease proposals in 6 countriesSub-Saharan Africa: West & Central Africa - 269 million for 12 disease proposals (including HSS requests) in 9 countries
TRP Funding RecommendationsProposals Not ApprovedBoard Decision Point on Round 10 (GF/B22/DP 27)download (PDF - 310 KB)
Detailed information on Round 10 is also available on The Global Fund Observer, an independent newsletter about the Global Fund provided by Aidspan:http://www.aidspan.org/documents/gfo/GFO-Issue-135.doc
Please note: So as not to distort the country statistics, 1 multi-country proposal has been counted as 1 country count, unless otherwise stated
* US dollar/Euro exchange rate, 1 December 2010. Please note that amounts per region and disease do not take into account any anticipated adjustments to be achieved during TRP clarifications and grant negotiations.
Round 9 and NSA - November 2009*
90 Round 9 disease proposals (including HSS requests) and National Strategy Applications (NSA) in 69 different countries approved, in principle, by the Board on 10 November 2009. It is noted that the TRP funding recommendations are collectively intended to be subject to a 10% adjustment downwards for efficiency, resulting in an adjusted maximum Phase 1 upper-ceiling funding of US$ 2.38 billion.
East Asia & the Pacific - US$ 473.6** million for 12 disease proposals (including HSS requests) in 7 countries Eastern Europe & Central Asia - US$ 107.6** million for 12 disease proposals in 10 countriesLatin America & the Caribbean - US$ 185.5** million for 17 disease proposals (including HSS requests) in 14 countriesNorth Africa & the Middle East - US$ 87.3** million for 5 disease proposals (including HSS requests) in 5 countriesSouth West Asia - US$ 233.8** million for 8 disease proposals (including HSS requests) in 6 countriesSub-Saharan Africa: East Africa - US$ 709.4** million for 11 disease proposals (including HSS requests) in 9 countriesSub-Saharan Africa: Southern Africa - US$ 258.9** million for 7 disease proposals in 6 countriesSub-Saharan Africa: West & Central Africa - US$ 592.1** million for 18 disease proposals (including HSS requests) in 12 countries
TRP Funding Recommendations:Proposals Not Approved:
Board Decision Point on Round 9 and NSA (GF/B20/DP11):download (PDF - 205 KB)
* USD exchange rate November 2009.
** Please note that amounts per region and disease do not include a 10% downward adjustment for efficiency anticipated to be achieved during TRP clarifications and grant negotiations.
Round 8 - November 2008
East Asia & the Pacific - US$ 387.4* million for 17 programs in 9 countries Eastern Europe & Central Asia - US$ 141.9* million for 16 programs in 9 countriesLatin America & the Caribbean - US$ 161.9* million for 11 programs in 10 countriesNorth Africa & the Middle East - US$ 147.4* million for 10 programs in 7 countriesSouth Asia - US $ 98.3* million for 8 programs in 5 countriesSub-Saharan Africa: East Africa - US$ 796.1* million for 15 programs in 10 countriesSub-Saharan Africa: Southern Africa - US$ 414.0* million for 13 programs in 5 countriesSub-Saharan Africa: West & Central Africa - US$ 912.3* million for 20 programs in 13 countries
TRP Funding RecommendationsProposals Not Approved
* Please note that amounts per region and disease do not include a 10% downward adjustment for efficiency anticipated to be achieved during TRP clarifications and grant negotiations.
Round 7 - November 2007
East Asia & the Pacific - US$ 92 million for 11 programs in 19 countries/ economies*Eastern Europe & Central Asia - US$ 38 million for 5 programs in 5 countries/ economiesLatin America & the Caribbean - US$ 54 million for 10 programs in 11 countries/ economies*North Africa & the Middle East - US$ 164 million for 10 programs in 7 countries/ economiesSouth Asia - US $97 million for 9 programs in 6 countries/economiesSub-Saharan Africa: East Africa - US$ 385 million for 9 programs in 8 countries/ economiesSub-Saharan Africa: Southern Africa - US$ 154 million for 8 programs in 6 countries/economiesSub-Saharan Africa: West & Central Africa - US$ 134 million for 11 programs in 8 countries/economies
*Including countries/economies targeted in the multi – country proposal
Round 6 - November 2006
East Asia & the Pacific - US$ 107 million in 8 countriesEastern Europe & Central Asia - US$ 119 million in 12 countryLatin America & the Caribbean - US$ 47 million in 4 countriesNorth Africa & the Middle East - US$ 70 million in 9 countriesSouth Asia - US$ 129 million in 5 countriesSub-Saharan Africa: East Africa - US$ 94 million in 7 countriesSub-Saharan Africa: Southern Africa - US$ 117 million in 4 countriesSub-Saharan Africa: West & Central Africa - US$ 159 million in 14 countries
TRP Funding RecommendationsList of Successful Appeals
Round 5 - September 2005
East Asia & the Pacific - US$ 128 million in 17 countriesEastern Europe & Central Asia - US$ 27 million in 8 countryLatin America & the Caribbean - US$ 54 million in 4 countriesNorth Africa & the Middle East - US$ 63 million in 4 countriesSouth Asia - US$ 24 million in 2 countriesSub-Saharan Africa: East Africa - US$ 135 million in 5 countriesSub-Saharan Africa: Southern Africa - US$ 124 million in 8 countriesSub-Saharan Africa: West & Central Africa - US$ 210 million in 12 countries
Round 4 - June 2004
Round 3 - November 2003
Round 2 - January 2003
Round 1 - April 2002
Summary of RCC Final Resubmission Wave Funding Decisions August 2010
Sao Tome e Principe (Malaria) - US$ 6,952,123
Summary of RCC Wave 8 Funding Decisions March 2010
Guyana - US$ 3,217,761Guatemala - US$ 100,966,712Lao PDR - US$ 11,642,882South Africa - US$ 143,086,769Uzbekistan - US$ 47,024,128
HIV and AIDS - US$ 290,719,768Malaria - US$ US$ 15,218,484
Summary of RCC Wave 7 Funding Decisions November 2009
China - US$ 404,818,780India - US$ 390,464,765Mongolia - US$ 8,540,561Namibia - US$ 230,943,957Tanzania - US$ 56,466,4747The Gambia - US$ 26,450,793Georgia - EUR 5,374,845
HIV and AIDS* - US$ 658,734,300Tuberculosis - US$ 423,087,271Malaria - US$ 43,814,713
*Including HSS cross-cutting interventions
Summary of RCC Wave 6 Funding Decisions May 2009
Bangladesh - US$ 81,312,404Belarus - US$ 14,340,567 Guyana - US$ 47,035,818 India - US$ 302,056,162 Nepal - US$ 31,950,775 Rwanda - US$ 13,700,861 Paraguay - US$ 5,481,613 Russia - EUR 9,288,623 Georgia - EUR 33,338,933
HIV and AIDS - US$ 488,669,764 Tuberculosis - US$ 31,420,449 Malaria - US$ 31,950,775
Summary of RCC Wave 5 Funding Decisions February 2009
Armenia - US$ 11,906,034Benin - US$ 60,422,029China - US$ 205,031,814Dominican Republic - US$ 6,405,790Madagascar - US$ 33,798,784Tajikistan - US$ 4,382,023
HIV and AIDS - US$ 216,937,848 Tuberculosis - US$ 10,787,813Malaria - US$ 94,220,813
Summary of RCC Wave 4 Funding Decisions October 2008
Dominican Republic - US $45,770,388El Salvador - US$ 14,398,031Ghana - US$ 89,764,243India - US$ 72,095,018Nicaragua - US$ 7,165,903
HIV and AIDS - US $60,168,419 Tuberculosis - US$ 79,260,921Malaria - US$ 89,764,243
Summary of RCC Wave 3 Funding Decisions July 2008
Bulgaria - US $28,021,697Cambodia - US$ 19,540,113China - US$ 42,840,814Cuba - US$ 9,772,998Ethiopia - US$ 342,574,327Haiti - US$ 46,136,317Honduras - US$ 3,453,657MCWP - US$ 21,009,881
HIV and AIDS - US $426,505,339 Tuberculosis - US$ 42,840,814Malaria - US$ 44,003,651
Summary of RCC Wave 2 Funding Decisions April 2008
Malawi - US$ 173,329,414Mongolia - US$ 3,481,740RMCC - US$ 14,384,472Thailand - US$ 56,157,021Philippines - US$ 117,136,422
HIV and AIDS - US$ 232,968,175Tuberculosis - US$ 78,037,991Malaria - US$ 53,482,903
Summary of RCC Wave 1 Funding Decisions November 2007
Burundi - US$19,694,151Honduras - US$ 25,121,194Mongolia - US$ 3,553,729Rwanda - US$ 21,346,817Tanzania - US$ 59,997,371
HIV and AIDS - US$ 47,187,023 Tuberculosis - US$ 8,454,963Malaria - US$ 151,443,365
AMFm Phase 1 - November 2009
Applications Not Approved